PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Institut Claudius Regaud
- Intervention
- Standard treatment: Control arm(other)
- Enrollment
- 510 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2023 – 2033
Study locations (30)
- Institut de Cancérologie de l'Ouest, Angers, France
- Institut Bergonié, Bordeaux, France
- CHU Brest, Brest, France
- Centre François Baclesse, Caen, France
- Centre Hospitalier Intercommunal de Créteil, Créteil, France
- Centre Georges François Leclerc, Dijon, France
- Centre Oscar Lambret, Lille, France
- CHRU Lille, Lille, France
- CHU Limoges, Limoges, France
- Centre Léon Bérard, Lyon, France
- Institut Paoli Calmettes, Marseille, France
- ICM Val d'Aurelle, Montpellier, France
- CHU Nîmes, Nîmes, France
- Hôpital Cochin, Paris, France
- Hôpital Européen Georges Pompidou, Paris, France
- +15 more locations on ClinicalTrials.gov
Collaborators
ARCAGY/ GINECO GROUP · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Gynecologic Cancer Intergroup (GCIG) · Grupo Español de Investigación en Cáncer de Ovario · Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies · Belgian Gynaecological Oncology Group · Swiss GO Trial Group · Institute of Cancer Research, United Kingdom · The Central and Eastern European Gynecologic Oncology Group · Hellenic Cooperative Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05581121 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital